Altimmune, Inc.
910 Clopper Road
Suite 210S
Gaithersburg
Maryland
20878
United States
Tel: 2406541450
Website: http://www.altimmune.com/
118 articles about Altimmune, Inc.
-
Patients treated with Altimmune’s investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of those taking the highest dose lost at least 20% of their body weight.
-
AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
-
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
11/7/2023
Altimmune, Inc. announced financial results for the three months ended September 30, 2023, and provided a business update.
-
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
10/31/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 and will provide a business update.
-
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
10/26/2023
Altimmune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program investigating pemvidutide for the treatment of NASH.
-
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
10/25/2023
Altimmune, Inc. today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023). Diseases (AA
-
Altimmune to Participate at Two Upcoming October 2023 Investor Conferences
10/17/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
9/26/2023
Altimmune, Inc. today announced that Dr. Louis J. Aronne will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting.
-
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or OverweightTop-line 48-week results from the trial expected Q4 2023
9/12/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight.
-
Altimmune to Participate at Two Upcoming September 2023 Investor Conferences
8/30/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
8/10/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ended June 30, 2023, and provided a business update.
-
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
8/3/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 and will provide a business update.
-
Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
8/1/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the Phase 2b IMPACT trial evaluating the efficacy and safety of pemvidutide in subjects with non-alcoholic steatohepatitis (NASH).
-
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
6/16/2023
Altimmune, Inc. announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, has been invited to participate on a Metabolic panel at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th, 2023 at 11:00 A.M. ET.
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
6/15/2023
Altimmune, Inc. announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria.
-
Altimmune to Participate at Two Upcoming June 2023 Investor Conferences
5/31/2023
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
5/11/2023
Altimmune, Inc. today announced financial results for the three months ended March 31, 2023, and provided a business update.
-
Altimmune to Participate at Two Upcoming Investor Conferences - May 8, 2023
5/8/2023
Altimmune, Inc. today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences.
-
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
5/4/2023
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.
-
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
4/11/2023
Altimmune, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB).